Related Experiment Video
Updated: Jun 23, 2026
11:12
Protocol for Relative Hydrodynamic Assessment of Tri-leaflet Polymer Valves
Published on: October 17, 2013
Polymeric heart valves: new materials, emerging hopes
Hossein Ghanbari1, Helene Viatge, Asmeret G Kidane
1Centre for Nanotechnology, Biomaterials and Tissue Engineering, Division of Surgery & Interventional Science, University College London, London, UK.
Trends in Biotechnology
|May 2, 2009
Summary
New polymeric heart valves (HVs) show promise as durable and functional alternatives to current devices. Advances in materials and design suggest future clinical success for these improved polymeric HVs.
Area of Science:
- Biomaterials Science
- Cardiovascular Engineering
- Polymer Science
Background:
- Heart valve replacements are critical cardiovascular devices with rising demand.
- Current options include mechanical and bioprosthetic valves, each with limitations.
- Polymeric heart valves (HVs) offer potential for improved durability and hemodynamics.
Purpose of the Study:
- To review recent advancements in polymeric HVs.
- To assess the potential of new-generation polymeric HVs for clinical application.
Main Methods:
- Review of recent scientific literature on polymers, nanomaterials, and biomaterials for HV development.
- Analysis of advancements in HV design and fabrication techniques.
Main Results:
- Early polymeric HVs faced durability issues, hindering commercialization.
- Recent progress in materials science and surface modification has enhanced biocompatibility and biostability.
- Improved design and fabrication methods are enabling long-lasting polymeric HVs.
Conclusions:
- New polymeric HVs demonstrate significant potential for long-term clinical use.
- Ongoing advancements suggest polymeric HVs will become a viable alternative in cardiovascular treatment.
- The next generation of polymeric HVs is poised for successful clinical integration.
More Related Videos
Related Concept Videos
01:16Heart Valves
The human heart is a complex organ with an intricate system of valves that regulate blood flow. There are two main types of valves: atrioventricular (AV) valves and semilunar valves.
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...